Immunocore Holdings plc

NasdaqGS:IMCR 株式レポート

時価総額：US$1.5b

Immunocore Holdings 配当と自社株買い

配当金 基準チェック /06

Immunocore Holdings配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.7%

バイバック利回り

総株主利回り-0.7%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブの更新 • May 19

IMCR: Future Upside Will Depend On Risky Oncology Pipeline Execution

Analysts now set Immunocore Holdings' fair value at $34, up $1 from $33. This reflects adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E after recent Street research highlighted a more cautious view on upside without clearer pipeline progress.
ナラティブの更新 • Apr 25

IMCR: Pipeline Upside Will Rely On Higher Risk Oncology Programs

Analysts cut their price target on Immunocore Holdings to $33 from $48, noting that Kimmtrak provides an established revenue base in uveal melanoma. They indicated that the investment case now depends more on what they view as higher risk pipeline outcomes.
ナラティブの更新 • Apr 08

IMCR: Pipeline Risk And Sector Rotation Will Shape Balanced 2026 Outlook

Analysts have reset their average price target on Immunocore to $33. Some frame this move as a sign that Kimmtrak's uveal melanoma revenue potential is closer to peak, with future upside hinging more on higher risk pipeline assets, while others still see room for value in the broader small to mid cap biotech group.
ナラティブの更新 • Mar 24

IMCR: Sector Rotation And Pipeline Risk Will Shape Balanced 2026 Outlook

Narrative Update The analyst fair value estimate for Immunocore Holdings has shifted from $38 to $33. This change reflects mixed Street views, with some analysts highlighting Kimmtrak's moderate market and maturing sales, while others point to broader biotech sentiment and pipeline potential as key factors for future returns.
ナラティブの更新 • Mar 10

IMCR: Sector Rotation And Capital Production Shift Will Shape Bullish 2026 Outlook

Analysts have nudged their fair value estimate for Immunocore Holdings up from $37.00 to $38.00, citing higher Street price targets from $40 to $55. These targets reflect growing confidence in small to mid cap biotech as some companies are seen as shifting from capital consumers to capital producers and benefiting from improving sector sentiment.
ナラティブの更新 • Feb 24

IMCR: Bullish View Will Center On 2026 Capital Producer Transition

Analysts have nudged their average price target on Immunocore higher, with recent moves such as a lift to $40 and an upgrade anchored by a new $55 target. These changes support a small upward adjustment in our modeled fair value to $66.57, alongside slightly higher discount rate and P/E assumptions.
ナラティブの更新 • Feb 08

IMCR: Sector Rotation And Pipeline Execution Will Shape Bullish 2026 Outlook

Narrative Update on Immunocore Holdings Analysts have lifted their average price target for Immunocore to a range anchored by the recent US$40 and US$55 targets. This reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples as they factor in improving sentiment toward small to mid cap biotech names.
ナラティブの更新 • Jan 24

IMCR: Balanced Outlook As Hepatitis B Data And Sector Rotation Shape 2026

Analysts have lifted their price target framework for Immunocore Holdings from about $24.93 to $37.00, reflecting recent Street research in which firms increased targets to as high as $55 and highlighted improving biotech fundamentals along with shifting investor attention toward small to mid cap commercial names. Analyst Commentary Recent Street research on Immunocore Holdings clusters around a common theme, with several firms linking their updated views to a broader shift in attention toward small to mid cap commercial biotech names.
ナラティブの更新 • Jan 10

IMCR: Bullish View Will Center On Advancing HBV TCR Bispecific Program

Narrative Update Analysts have lifted their blended price target for Immunocore, with recent moves such as a Morgan Stanley increase to $40 and a UBS move to $55 contributing to a higher implied fair value of about $66.36, based on updated assumptions for growth, margins and a higher future P/E multiple. Analyst Commentary Recent Street research around Immunocore centers on shifting views of small to mid cap biotech, updated price targets, and how investors might think about the balance between potential upside and execution risk.
Seeking Alpha • Nov 08

Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst

Summary Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentiment says to "Hold" based on slowing sales growth, but this does not factor in the broad pipeline. To me, this is a qualified "Buy" assuming they can take any one of their many projects to the finish line. Read the full article on Seeking Alpha
分析記事 • Aug 02

Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Jun 10

Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders have had their patience rewarded with a 27% share price jump in...
Seeking Alpha • Apr 27

Immunocore Holdings: A Name On My Watch List

Summary Immunocore Holdings' shares have fallen over 60% since February 2024 due to lack of catalysts and competition for its main product, Kimmtrak. Kimmtrak, approved for metastatic uveal melanoma, faces market saturation and competition, but label expansion could significantly increase its market potential. Immunocore's pipeline includes promising early-stage oncology and infectious disease programs, but pivotal data for key trials won't be available until 2H26 or later. An analysis around Immuncore Holdings follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Apr 26

Improved Revenues Required Before Immunocore Holdings plc (NASDAQ:IMCR) Shares Find Their Feet

Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right...
User avatar
新しいナラティブ • Mar 23

AI Tools And Global Expansion Will Broaden KIMMTRAK's Market Reach

Expansion into less dense U.S. markets and international launches are key to driving revenue growth for Immunocore's KIMMTRAK.
分析記事 • Mar 04

Is Immunocore Holdings (NASDAQ:IMCR) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Feb 27

Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point

Summary Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries inherent biotech industry risks. IMCR's financials show increased product revenue and net income, with substantial cash reserves to support ongoing and future developments. Read the full article on Seeking Alpha
分析記事 • Jan 08

There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding

Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a strong buy...
Seeking Alpha • Dec 10

Immunocore Is Adequately Valued, But Its Prospects Are Uncertain

Summary Immunocore's KIMMTRAK, targeting metastatic uveal melanoma, is FDA-approved and has shown significant clinical efficacy, with potential label expansions in cutaneous and adjuvant uveal melanoma. The company's ImmTAX platform develops TCR-based bispecific molecules, with ongoing trials for Tebentafusp and Brenetafusp in various cancers, showing promising early results. Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's strength and clarity. Despite recent stock declines and cautious market sentiment, future trial successes could make current prices attractive for conservative investors. Read the full article on Seeking Alpha
分析記事 • Oct 24

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Sep 19

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 6.1x might make it look like a buy right...
Seeking Alpha • Aug 12

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Summary Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V. I also believe IMCR could be a viable takeover target, given its diverse IP, growing revenues, and strong financials, which could potentially attract big pharma. Despite premium valuation risks, Immunocore's financials are robust, making it a "buy" for long-term investors familiar with biotech risks. Read the full article on Seeking Alpha
分析記事 • Jul 24

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$58.75 Immunocore...
分析記事 • Jun 16

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

To the annoyance of some shareholders, Immunocore Holdings plc ( NASDAQ:IMCR ) shares are down a considerable 28% in...
分析記事 • May 11

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • May 11

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders are probably feeling a little disappointed, since its shares fell...
分析記事 • Apr 05

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$83.30 Immunocore...
分析記事 • Jan 22

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jan 21

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Summary Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunotherapies for cancer, infectious, and autoimmune diseases. The company's stock is up around 80% since late October and now is solidly in mid-cap territory. The stock has gotten shout outs from Barron's and Robert W. Baird to start the new year. Are further gains ahead in 2024 for Immunocore shareholders?  An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Dec 18

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Immunocore Holdings plc ( NASDAQ:IMCR ) shares have had a really impressive month, gaining 37% after a shaky period...

決済の安定と成長

配当データの取得

安定した配当: IMCRの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: IMCRの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Immunocore Holdings 配当利回り対市場
IMCR 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (IMCR)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.2%
業界平均 (Biotechs)2.4%
アナリスト予想 (IMCR) (最長3年)0%

注目すべき配当: IMCRは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: IMCRは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: IMCRの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: IMCRが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/29 21:15
終値2026/05/29 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Immunocore Holdings plc 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27

アナリスト機関
Jack AllenBaird
Suranjit MukherjeeBTIG
Justin ZelinBTIG